Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aromatase inhibitors + fulvestrant
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
A combination therapy approach that targets estrogen signaling through complementary mechanisms for the treatment of hormone receptor-positive (HR+) breast cancer. Aromatase inhibitors reduce estrogen production by blocking the aromatase enzyme, while fulvestrant is a selective estrogen receptor degrader (SERD) that blocks and degrades estrogen receptors. This dual approach may help overcome or delay endocrine resistance in advanced breast cancer.
- Other names
- AI + fulvestrantaromatase inhibitor and fulvestrantendocrine therapy
02
Targets
ER (Estrogen receptor)CYP19A1 (Aromatase)
Beyond the preview
Go deeper on aromatase inhibitors + fulvestrant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aromatase inhibitors + fulvestrant.